Clinical research

Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study

EuroIntervention 2012;8:214-224.

Josep Gomez-Lara
Josep Gomez-Lara1, MD; Roberto Diletti1, MD; Salvatore Brugaletta1, MD; Yoshinobu Onuma1, MD; Vasim Farooq1, MB, ChB, MRCP; Leif Thuesen2, MD; Dougal McClean3, MD; Jacques Koolen4, MD, PhD; John A Ormiston5, MB,ChB, PhD; Stefan Windecker6, MD; Robert Whitbourn7, MD; Dariusz Dudek8, MD; Cécile Dorange9, MSc; Susan Veldhof9, RN; Richard Rapoza10, PhD; Evelyn Regar1, MD, PhD; Hector M. Garcia-Garcia1, MD, PhD; Patrick W. Serruys1<
1. ThoraxCenter, Erasmus MC, Rotterdam, The Netherlands; 2. Skejby Sygehus, Aarhus University Hospital, Skejby, Denmark; 3. Christchurch Hospital, Christchurch, New Zealand; 4. Catharine Ziekenhuis, Eindhoven, The Netherlands; 5. Auck

Aims: Bioresorbable vascular scaffolds (BVS) present different mechanical properties as compared to metallic platform stents. Therefore,

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

angiographycoronary artery diseaseoptical coherence tomographyoptimal deploymentbioresorbable scaffold
Read next article
Serial greyscale and radiofrequency intravascular ultrasound assessment of plaque modification and vessel geometry at proximal and distal edges of bare metal and first-generation drug-eluting stents

Latest news